The United States Food and Drug Administration (USFDA) have given final permission to ZydusLifesciences Limited to manufacture and market Ephedrine Sulphate Injection USP, 50 mg/mL single-dose vials(USRLD: Akovaz® Injection).

Ephedrine Sulfate Injection is advisedfor the treatment of clinically significant hypotension that occurs during anaesthesia. The medication will be manufacture at Jarod, close to Vadodara, India.

 According to IQVIA MAT Mar. 2023 report, the yearly sales of Ephedrine Sulphate Injection USP, 50 mg/mL, were 52 million dollars in United States.

Since the filing procedure began in FY 2003–2004, the group has received 368 approvals and has submitted over 440* ANDAs.